Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Cancer Research Microarray Detects CNVs and LOH on a Single Chip

By BiotechDaily International staff writers
Posted on 01 Apr 2013
Print article
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A novel, optimized cytogenetic cancer research microarray system enables reliable, simultaneous detection of both copy number variations (CNVs) and loss of heterozygosity (LOH), and includes software designed to facilitate superior data analysis and interpretation.

Oxford Gene Technology (OGT; Oxfordshire, UK) introduces the “CytoSure Cancer +SNP array” designed to improve the accuracy and efficiency of molecular cancer research. The new microarray combines long oligo array comparative genomic hybridization (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both CNVs) and LOH on a single chip (4 arrays of 180k spots). The array has been optimized in collaboration with Prof. Jacqueline Schoumans from the Lausanne University Hospital (Switzerland), an expert in both aCGH and cancer genomics. Unique to the proprietary CytoSure Cancer +SNP array, any reference sample can be used for analysis without changes to the standard aCGH protocol and, thanks to novel SNP probe chemistry, no restriction digest is required. The capacity to use matched samples is a particular advantage for research into genetic aberrations in cancer, enabling any constitutional abnormalities to be filtered out.

Prof. Schoumans commented, “The development of a new microarray with the capacity to detect both CNVs and LOH simultaneously was vital for improving the efficiency and quality of our research. By working very closely with the technical experts at OGT, we have constructed a new array that allows users to simultaneously screen a wide genomic background for CNVs and LOH, while also enabling in-depth CNV analysis on 1,500 known cancer-associated genes. This approach produces accurate and insightful data, with all aberrations clearly highlighted and filtered using OGT’s excellent CytoSure Interpret Software.”

“The new CytoSure Cancer +SNP array forms part of OGT’s ongoing strategy to design specialized microarrays to help increase our understanding of cancer formation and development [and to facilitate] research into more efficacious, targeted treatments,” added James Clough, Executive Vice President Commercial at OGT. The 60-mer oligonucleotide probes utilized in the array provide a high signal-to-noise ratio and highly sensitive detection; this makes them ideal for research into complex malignant tissues. With OGT’s innovative CytoSure Interpret Software, data analysis is rapid, reliable, and simple to carry out, including updated features (such as the B-allele frequency plot) that have been optimized for the identification of biologically relevant genomic variants in tumor samples.

Related Links:
Oxford Gene Technology
CytoSure Cancer +SNP array
CytoSure Interpret Software



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.